Caladrius Biosciences Inc. [NASDAQ: CLBS] gained 13.37% or 0.25 points to close at $2.12 with a heavy trading volume of 5806361 shares. The company report on February 19, 2021 that Caladrius Biosciences to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time.
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announced that the Company will report its financial results for the three and twelve months ended December 31, 2020 on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time.
Live Conference Call and Webcast Details:.
It opened the trading session at $1.919, the shares rose to $2.18 and dropped to $1.91, the range by which the price of stock traded the whole day. The daily chart for CLBS points out that the company has recorded 11.58% gains over the past six months. However, it is still -101.9% lower than its most recent low trading price.
If we look at the average trading volume of 5.06M shares, CLBS reached to a volume of 5806361 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Caladrius Biosciences Inc. [CLBS]:
Dawson James have made an estimate for Caladrius Biosciences Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 18, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on November 20, 2018, representing the official price target for Caladrius Biosciences Inc. stock. Previously, the target price had yet another raise to $6.50, while Chardan Capital Markets analysts kept a Buy rating on CLBS stock.
The Average True Range (ATR) for Caladrius Biosciences Inc. is set at 0.38 The Price to Book ratio for the last quarter was 1.04, with the Price to Cash per share for the same quarter was set at 0.72.
Trading performance analysis for CLBS stock
Caladrius Biosciences Inc. [CLBS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.55. With this latest performance, CLBS shares dropped by -7.42% in over the last four-week period, additionally plugging by 11.58% over the last 6 months – not to mention a drop of -28.14% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLBS stock in for the last two-week period is set at 49.47, with the RSI for the last a single of trading hit 47.01, and the three-weeks RSI is set at 51.09 for Caladrius Biosciences Inc. [CLBS]. The present Moving Average for the last 50 days of trading for this stock 1.90, while it was recorded at 2.14 for the last single week of trading, and 1.89 for the last 200 days.
Caladrius Biosciences Inc. [CLBS]: A deeper dive into fundamental analysis
Return on Total Capital for CLBS is now -77.28, given the latest momentum, and Return on Invested Capital for the company is -65.45. Return on Equity for this stock declined to -66.14, with Return on Assets sitting at -53.98. When it comes to the capital structure of this company, Caladrius Biosciences Inc. [CLBS] has a Total Debt to Total Equity ratio set at 4.70. Additionally, CLBS Total Debt to Total Capital is recorded at 4.49, with Total Debt to Total Assets ending up at 3.60. Long-Term Debt to Equity for the company is recorded at 3.00, with the Long-Term Debt to Total Capital now at 2.86.
Reflecting on the efficiency of the workforce at the company, Caladrius Biosciences Inc. [CLBS] managed to generate an average of -$717,074 per employee.Caladrius Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.90 and a Current Ratio set at 9.90.
Caladrius Biosciences Inc. [CLBS]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Caladrius Biosciences Inc. posted -0.47/share EPS, while the average EPS was predicted by analysts to be reported at -0.34/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -38.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLBS.
An analysis of insider ownership at Caladrius Biosciences Inc. [CLBS]
There are presently around $5 million, or 6.80% of CLBS stock, in the hands of institutional investors. The top three institutional holders of CLBS stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 1,045,855, which is approximately 12.79% of the company’s market cap and around 1.70% of the total institutional ownership; VANGUARD GROUP INC, holding 342,608 shares of the stock with an approximate value of $0.73 million in CLBS stocks shares; and ANSON FUNDS MANAGEMENT LP, currently with $0.51 million in CLBS stock with ownership of nearly New of the company’s market capitalization.
Positions in Caladrius Biosciences Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 15 institutional holders increased their position in Caladrius Biosciences Inc. [NASDAQ:CLBS] by around 569,778 shares. Additionally, 8 investors decreased positions by around 186,601 shares, while 13 investors held positions by with 1,526,284 shares. The mentioned changes placed institutional holdings at 2,282,663 shares, according to the latest SEC report filing. CLBS stock had 5 new institutional investments in for a total of 346,543 shares, while 3 institutional investors sold positions of 120,966 shares during the same period.